In this issue of GOLD, we take a dive into the pharmaceutical industry’s key news stories from the past few months, covering the latest mergers and acquisitions, approvals, and clinical trial results.
03 September
BMS obtains exclusive global license for Evotec’s neurodegenerative drug
06 September
AstraZeneca and Amgen’s Tezepelumab shows positive phase III results for severe asthma
07 September
ILC Therapeutics announces completion of £3.5m pre-IPO funding round
08 September
Sanofi seeks to acquire Kadmon to expand its transplant portfolio
10 September
MHRA approves marketing authorisation for Pfizer’s JAK1 inhibitor Cibinqo
14 September
Beckley Psytech announces ‘world-first’ trial of psilocybin for headaches
20 September
AstraZeneca and Daiichi Sankyo’s Enhertu decreases progression or death from breast cancer by 72%
21 September
FDA approves Exlixis’ Cabometyx for the treatment of thyroid cancer
04 October
MSD’s molnupiravir halves hospitalisation and death in COVID-19 patients
08 October
NUC-7738 drug derived from fungus found to be beneficial in treating cancer
13 October
Sanofi’s BTK inhibitor tolebrutinib shows promising long-term data as MS treatment
20 October
FSD and Covar to explore psychoactive compound LUCID-Psych as treatment for major depressive disorders